Key Points
- Director Blake Borgeson sold 220,000 shares of Recursion on Dec. 2 at an average of $4.37 for about $961,400, reducing his stake by 3.10% to 6,869,863 shares (SEC filing).
- Shares trade near $4.80 amid weak fundamentals — quarterly revenue fell 80.1% year‑over‑year and the company reports deeply negative margins and ROE; analysts' consensus is a Hold with a $7.25 price target.
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) Director Blake Borgeson sold 220,000 shares of the stock in a transaction that occurred on Tuesday, December 2nd. The stock was sold at an average price of $4.37, for a total value of $961,400.00. Following the transaction, the director owned 6,869,863 shares in the company, valued at $30,021,301.31. The trade was a 3.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Recursion Pharmaceuticals Stock Down 2.5%
Recursion Pharmaceuticals stock opened at $4.80 on Friday. The company has a market capitalization of $2.50 billion, a PE ratio of -2.66 and a beta of 0.94. Recursion Pharmaceuticals, Inc. has a 12-month low of $3.79 and a 12-month high of $12.36. The firm's fifty day moving average is $5.13 and its 200 day moving average is $5.12. The company has a quick ratio of 4.60, a current ratio of 4.60 and a debt-to-equity ratio of 0.01.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.02. The firm had revenue of $5.18 million for the quarter, compared to analyst estimates of $19.36 million. Recursion Pharmaceuticals had a negative net margin of 1,637.81% and a negative return on equity of 72.74%. The business's quarterly revenue was down 80.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.34) earnings per share. As a group, sell-side analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.
Institutional Trading of Recursion Pharmaceuticals
Several institutional investors and hedge funds have recently modified their holdings of RXRX. Brighton Jones LLC boosted its position in shares of Recursion Pharmaceuticals by 49.4% during the fourth quarter. Brighton Jones LLC now owns 20,261 shares of the company's stock valued at $137,000 after buying an additional 6,699 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Recursion Pharmaceuticals in the 1st quarter valued at $57,000. Cetera Investment Advisers lifted its stake in Recursion Pharmaceuticals by 22.6% during the 1st quarter. Cetera Investment Advisers now owns 75,788 shares of the company's stock valued at $401,000 after acquiring an additional 13,955 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Recursion Pharmaceuticals by 15.5% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 76,730 shares of the company's stock worth $406,000 after acquiring an additional 10,272 shares during the last quarter. Finally, LPL Financial LLC boosted its holdings in Recursion Pharmaceuticals by 15.6% during the 1st quarter. LPL Financial LLC now owns 425,090 shares of the company's stock worth $2,249,000 after acquiring an additional 57,305 shares during the last quarter. 89.06% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of brokerages have recently weighed in on RXRX. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Recursion Pharmaceuticals in a research report on Wednesday, October 8th. Needham & Company LLC reissued a "buy" rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a research report on Thursday, September 11th. Two analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Recursion Pharmaceuticals presently has an average rating of "Hold" and a consensus price target of $7.25.
Read Our Latest Report on RXRX
Recursion Pharmaceuticals Company Profile
(
Get Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
